• Early identification of those infected before they become infectious.
  • Orders of magnitude more sensitive than current tests, leading to fewer false negatives.
  • Enabling safe and high-confidence reopening of businesses and schools.


  • Self-collected, saliva-based test minimizes individual discomfort and organizational disruption.
  • Eliminates the need for specialized collection personnel.
  • Provides a superior sample source for viral detection.

Ultra-High Capacity

  • Tens-of-thousands of results per day per AMPD module.
  • 24 hour standard time to result, with same-day reporting possible.
  • Angstrom's goal is to deliver more than 1,000,000 results per day in 2021.


  • Definitive accuracy and 24-hour turnaround at less than 25% of the cost of current PCR diagnostics
Illustration of multiple pathogens


  • Unrivaled ability to add target pathogens without sacrificing throughput or accuracy, and without a material change in costs
  • SARS-CoV-2 (October 2020)
  • SARS-CoV-2 + Influenza A/B (Q4 2020)
  • Respiratory Panel (By Early 2021)